SPRY ARS PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ARS PHARMACEUTICALS INC reported revenue of $33.7M (up 114.2% from a year earlier), net income of −$62.3M and diluted EPS of −$0.63; over the last four quarters revenue was $117M and net income −$215M; for the fiscal year ended December 2025 revenue was $84.3M, down 5.5% on the year before.
SPRY annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $84.3M, gross profit n/a, operating income −$179M, net income −$171M (margin -203.3%), EPS −$1.74
- Fiscal year ended Dec 2024: revenue $89.1M, gross profit n/a, operating income −$3.08M, net income $8.00M (margin 9.0%), EPS $0.08
- Fiscal year ended Dec 2023: revenue $30.0K, gross profit n/a, operating income −$67.5M, net income −$54.4M (margin -181216.7%), EPS −$0.57
- Fiscal year ended Dec 2022: revenue $1.32M, gross profit n/a, operating income −$35.5M, net income −$34.7M (margin -2635.4%), EPS −$0.87
- Fiscal year ended Dec 2021: revenue $5.51M, gross profit n/a, operating income −$19.5M, net income −$20.2M (margin -367.7%), EPS −$0.70
SPRY quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $33.7M (up 114.2% year over year), net income −$62.3M, EPS −$0.63
- Quarter ended Mar 31, 2026: revenue $22.7M (up 184.5% year over year), net income −$60.6M, EPS −$0.61
- Quarter ended Dec 31, 2025 (from the annual report): revenue $28.1M (down 67.6% year over year), net income −$41.3M, EPS −$0.41
- Quarter ended Sep 30, 2025: revenue $32.5M (up 1471.6% year over year), net income −$51.2M, EPS −$0.52
- Quarter ended Jun 30, 2025: revenue $15.7M (up 3043.4% year over year), net income −$44.9M, EPS −$0.46
- Quarter ended Mar 31, 2025: revenue $7.97M, net income −$33.9M, EPS −$0.35
- Quarter ended Dec 31, 2024 (from the annual report): revenue $86.6M, net income $49.9M, EPS $0.52
- Quarter ended Sep 30, 2024: revenue $2.07M, net income −$19.1M, EPS −$0.20
- Quarter ended Jun 30, 2024: revenue $500K (up 4900.0% year over year), net income −$12.5M, EPS −$0.13
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$10.3M, EPS −$0.11
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$7.17M, EPS −$0.07
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$14.9M, EPS −$0.16
- Quarter ended Jun 30, 2023: revenue $10.0K (down 97.8% year over year), net income −$17.4M, EPS −$0.18
- Quarter ended Mar 31, 2023: revenue $20.0K (down 97.0% year over year), net income −$15.0M, EPS −$0.16
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$14.4M, EPS −$0.21
- Quarter ended Sep 30, 2022: revenue $189K, net income −$6.58M, EPS −$0.21
- Quarter ended Jun 30, 2022: revenue $464K, net income −$6.42M, EPS −$0.21
- Quarter ended Mar 31, 2022: revenue $663K, net income −$7.25M, EPS −$0.24
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $45.8M, EPS $1.19
- Quarter ended Sep 30, 2021: revenue n/a, net income −$22.7M, EPS −$0.65
SPRY cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$171M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $13.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$59.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$40.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$17.6M, share buybacks n/a
SPRY balance sheet
- Jun 30, 2026: cash $8.16M, total assets $249M, total liabilities $237M, shareholders' equity $12.5M
- Mar 31, 2026: cash $24.3M, total assets $288M, total liabilities $226M, shareholders' equity $61.3M
- Dec 31, 2025: cash $41.3M, total assets $328M, total liabilities $213M, shareholders' equity $114M
- Sep 30, 2025: cash $59.6M, total assets $373M, total liabilities $225M, shareholders' equity $148M
- Jun 30, 2025: cash $51.5M, total assets $313M, total liabilities $121M, shareholders' equity $192M
- Mar 31, 2025: cash $39.9M, total assets $327M, total liabilities $98.3M, shareholders' equity $229M
- Dec 31, 2024: cash $50.8M, total assets $351M, total liabilities $94.4M, shareholders' equity $257M
- Sep 30, 2024: cash $39.7M, total assets $218M, total liabilities $16.6M, shareholders' equity $201M
What is SPRY's revenue?
ARS PHARMACEUTICALS INC reported $117M of revenue over its last four quarters, through June 30, 2026.
Is SPRY profitable?
No. ARS PHARMACEUTICALS INC lost $215M over the last four quarters.
What is SPRY's EPS?
Diluted earnings per share over the last four quarters were −$2.17; −$0.63 in the latest quarter.